News

University College London begins preclinical studies to develop a treatment for Niemann Pick C disease with support from the Columbus Foundation

Cyclo Therapeutics to Participate in Inaugural Emerging Growth Virtual Conference

Cyclo Therapeutics Appoints Russ Belden as Acting Chief Commercial Officer

We are pleased to share the following update from Cyclo Therapeutics entitled 'Cyclo Therapeutics Appoints Russ Belden as Acting Chief Commercial Officer'...

Cyclo Therapeutics Receives Positive Opinion from the Paediatric Committee of the European Medicines Agency on the Agreement of a Paediatric Investigation Plan for Trappsol® Cyclo™

We are pleased to share the latest update from Cyclo Therapeutics entitled: Cyclo Therapeutics Receives Positive Opinion from the Paediatric Committee of the European Medicines Agency on the Agreement of a Paediatric Investigation Plan for Trappsol® Cyclo™...

Cyclo Therapeutics Announces Last Patient Last Visit in Phase 1/2 Trial Evaluating Trappsol® Cyclo™ for the Treatment of Niemann-Pick Disease Type C

Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families suffering from disease, today announced that the last patient completed their last visit in the Phase 1/2 study evaluating Trappsol® Cyclo™...